Publications

228 Publications visible to you, out of a total of 228

Abstract

Not specified

Authors: Ulrike Mueller, L. Issler, Gert Funkat, Alfred Winter

Date Published: 2009

Publication Type: InCollection

Abstract

Not specified

Authors: Franziska Jahn, Lutz Ißler, Alfred Winter, Katsuhiko Takabayashi

Date Published: 2009

Publication Type: Journal article

Abstract (Expand)

BACKGROUND: The role of intensive insulin therapy in patients with severe sepsis is uncertain. Fluid resuscitation improves survival among patients with septic shock, but evidence is lacking to support the choice of either crystalloids or colloids. METHODS: In a multicenter, two-by-two factorial trial, we randomly assigned patients with severe sepsis to receive either intensive insulin therapy to maintain euglycemia or conventional insulin therapy and either 10% pentastarch, a low-molecular-weight hydroxyethyl starch (HES 200/0.5), or modified Ringer's lactate for fluid resuscitation. The rate of death at 28 days and the mean score for organ failure were coprimary end points. RESULTS: The trial was stopped early for safety reasons. Among 537 patients who could be evaluated, the mean morning blood glucose level was lower in the intensive-therapy group (112 mg per deciliter [6.2 mmol per liter]) than in the conventional-therapy group (151 mg per deciliter [8.4 mmol per liter], P<0.001). However, at 28 days, there was no significant difference between the two groups in the rate of death or the mean score for organ failure. The rate of severe hypoglycemia (glucose level, < or = 40 mg per deciliter [2.2 mmol per liter]) was higher in the intensive-therapy group than in the conventional-therapy group (17.0% vs. 4.1%, P<0.001), as was the rate of serious adverse events (10.9% vs. 5.2%, P=0.01). HES therapy was associated with higher rates of acute renal failure and renal-replacement therapy than was Ringer's lactate. CONCLUSIONS: The use of intensive insulin therapy placed critically ill patients with sepsis at increased risk for serious adverse events related to hypoglycemia. As used in this study, HES was harmful, and its toxicity increased with accumulating doses. (ClinicalTrials.gov number, NCT00135473.)

Authors: F. M. Brunkhorst, C. Engel, F. Bloos, A. Meier-Hellmann, M. Ragaller, N. Weiler, O. Moerer, M. Gruendling, M. Oppert, S. Grond, D. Olthoff, U. Jaschinski, S. John, R. Rossaint, T. Welte, M. Schaefer, P. Kern, E. Kuhnt, M. Kiehntopf, C. Hartog, C. Natanson, M. Loeffler, K. Reinhart

Date Published: 10th Jan 2008

Publication Type: Not specified

Human Diseases: bacterial infectious disease

Abstract

Not specified

Authors: U. Müller, Elske Ammenwerth, B. Brigl, S. Gräber, R. Gruetz, A. Häber, E. Kuhn, A. Kutscha, Pierre-Michael Meier, B. Wentz, Alfred Winter

Date Published: 2008

Publication Type: Journal article

Abstract

Not specified

Authors: Rada Hussein, Alfred Winter

Date Published: 2008

Publication Type: Journal article

Abstract

Not specified

Authors: Petra Knaup-Gregori, Christian Mauro, Jan Marco Leimeister, Alfred Winter

Date Published: 2008

Publication Type: Journal article

Abstract

Not specified

Authors: Ruth Breu, John C. Mitchell, Janos Sztipanovits, Alfred Winter

Date Published: 2008

Publication Type: Misc

Powered by
(v.1.13.0-master)
Copyright © 2008 - 2021 The University of Manchester and HITS gGmbH
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig

By continuing to use this site you agree to the use of cookies